Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2029

2020-09-15
Price :
Published : Sep-2020
No. of Pages : 37

Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2029

Summary

Amyotrophic lateral sclerosis (ALS) is a group of rare but fatal neurodegenerative diseases that primarily involve the nerve cells (neurons) in the brain and spinal cord responsible for controlling voluntary muscle movement like chewing, walking, and talking (National Institute of Neurological Disorders and Stroke, 2020). ALS is often called Lou Gehrig’s disease, after the baseball player who was diagnosed with the disease in 1939 (Mayo Clinic, 2019). Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear. Currently, there is no cure for ALS and no effective treatment to stop, or reverse, the progression of the disease (National Institute of Neurological Disorders and Stroke, 2020).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. The disease definition for ALS was based on El Escorial criteria or the ICD-9 criteria (ICD-9 code: 335.2). The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of ALS in the 8MM, segmented by age, sex, and type.

The following data describes epidemiology of ALS. In the 8MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of ALS from 74,614 cases in 2019 to 80,483 cases in 2029 at an AGR of 0.79% during the forecast period. In the 8MM, the diagnosed prevalent cases of ALS will increase from 57,750 cases in 2019 to 65,886 cases in 2029 at an AGR of 1.41% during the forecast period. ALS is predominant in the older age group globally and its prevalence increases with advancing age until the 70s or 80s. These trends are reflected in GlobalData’s forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.

Scope

– The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Report provides an overview of the risk factors and global trends of ALS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
– The report includes a 10-year epidemiological forecast for the prevalent cases of ALS (total and diagnosed) segmented by sex, age (ages ?40 years), and type (familial and sporadic) in these markets. In addition, the model corresponding to this report includes incident cases of ALS for ages 40 years and older.
– The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Amyotrophic Lateral Sclerosis Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global ALS market.
– Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
– Understand magnitude of ALS population by severity at diagnosis.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Pathology Market by Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), End-User (Pharmaceutical Companies, Hospitals) – Global Forecast to 2025

“The digital pathology market is projected to grow at a CAGR of 13.8% during the forecast period (2020–2025).” The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8% during the forecast period. The key factors driving the growth of this market include the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, growing application of digital pathology in drug development & companion diagnostics, and increasing initiatives by industry players. However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent. “Adoption of artificial intelligence is expected to increase during the forecast period.” The adop......
$4950

Netherlands Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Netherlands Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "Netherlands Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in the Netherlands. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-hous......
$1995

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol), Region – Global Forecast to 2025

The pharmaceutical packaging equipment market is expected to grow at a CAGR of 7.4% in the forecast period. The global pharmaceutical packaging equipment market size is projected to reach USD 10.4 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 7.4% from 2020 to 2025. The growth of the market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible & integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, and the introduction of regulatory standards on packaging & stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are expected to restrain market growth to a cer......
$4950

Central Retinal Vein Occlusion Disease – Global Clinical Trials Review, H2, 2020

Central Retinal Vein Occlusion Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Central Retinal Vein Occlusion Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Central Retinal Vein Occlusion Clinical trials scenario. This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Malignant Pleural Effusion Disease – Global Clinical Trials Review, H2, 2020

Malignant Pleural Effusion Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Malignant Pleural Effusion Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Malignant Pleural Effusion Clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Pleural Effusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Primary Immune Deficiency (PID) Disease – Global Clinical Trials Review, H2, 2020

Primary Immune Deficiency (PID) Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Primary Immune Deficiency (PID) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Primary Immune Deficiency (PID) Clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Immune Deficiency (PID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Rabies Disease – Global Clinical Trials Review, H2, 2020

Rabies Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Rabies Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Rabies Clinical trials scenario. This report provides top line data relating to the clinical trials on Rabies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are c......
$2500

House Dust Mite Allergy Disease – Global Clinical Trials Review, H2, 2020

House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of House Dust Mite Allergy Clinical trials scenario. This report provides top line data relating to the clinical trials on House Dust Mite Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Measles Disease – Global Clinical Trials Review, H2, 2020

Measles Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Measles Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Measles Clinical trials scenario. This report provides top line data relating to the clinical trials on Measles. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials a......
$2500

Menorrhagia Disease – Global Clinical Trials Review, H2, 2020

Menorrhagia Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Menorrhagia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Menorrhagia Clinical trials scenario. This report provides top line data relating to the clinical trials on Menorrhagia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. C......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy